CTMX Q4 2019 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$822M

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M-27.8% YoY

Gross Profit

$8M100.0% margin

Operating Income

-$37M-451.5% margin

Net Income

-$35M-428.3% margin

EPS (Diluted)

$-0.78

QoQ Revenue Growth

-22.7%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$30M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$341M

Total Liabilities

$290M

Stockholders' Equity

$51M

Cash & Equivalents

$188M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$11M	-27.8%
Gross Profit	$8M	$11M	-27.8%
Operating Income	-$37M	-$26M	-44.8%
Net Income	-$35M	-$32M	-10.0%